强化他汀降脂治疗的发展方向

被引:11
作者
刘捷颖
严晓伟
机构
[1] 中国医学科学院中国协和医科大学北京协和医院
关键词
低密度脂蛋白胆固醇; 动脉粥样硬化; 强化他汀治疗; 依折麦布;
D O I
暂无
中图分类号
R543.5 [动脉疾病];
学科分类号
1002 ; 100201 ;
摘要
血浆胆固醇尤其是低密度脂蛋白胆固醇(LDL-C)是动脉粥样硬化斑块的主要组成部分。虽然临床研究表明强化他汀治疗在降低LDL-C水平以及对临床终点事件的影响方面均优于常规他汀治疗,但目前他汀类药物在临床实际应用中使用率较低,降脂幅度有限,药物的肝脏和肌肉毒性等问题,使得强化他汀降脂难以完成其使命。因此,强化降脂治疗的发展方向是联合应用具有不同降胆固醇机制的药物。依折麦布是一种肠道胆固醇吸收抑制剂,与他汀类药物合用不仅具有强大的降低LDL-C作用,还可以减少他汀药物的剂量,从而降低不良反应的发生率。
引用
收藏
页码:43 / 46
页数:4
相关论文
共 4 条
[1]  
Determinants of Arterial Wall Remodeling During Lipid-Lowering Therapy: Serial Intravascular Ultrasound Observations From the Reversal of Atherosclerosis With Aggressive Lipid Lowering Therapy (REVERSAL) Trial[J] . Paul Schoenhagen,E Murat Tuzcu,Carolyn Apperson-Hansen,Chaohui Wang,Kathy Wolski,Songhua Lin,Ilke Sipahi,Stephen J. Nicholls,William A. Magyar,Aaron Loyd,Tammy Churchill,Tim Crowe,Steven E. Nissen.Circulation . 2006 (24)
[2]  
A Community-Based, Randomized Trial of Ezetimibe Added to Statin Therapy to Attain NCEP ATP III Goals for LDL Cholesterol in Hypercholesterolemic Patients: The Ezetimibe Add-On to Statin for Effectiveness (EASE) Trial[J] . Thomas A. Pearson,Margo A. Denke,Patrick E. McBride,Wendy P. Battisti,William E. Brady,Joanne Palmisano.Mayo Clinic Proceedings . 2005 (5)
[3]  
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial[J] . The Lancet . 2002 (9326)
[4]  
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies[J] . Harold E Bays,Paul B Moore,Margaret A Drehobl,Sidney Rosenblatt,Phillip D Toth,Carlos A Dujovne,Robert H Knopp,Leslie J Lipka,Alexandre P LeBeaut,Bo Yang,Lillian E Mellars,Cynthia Cuffie-Jackson,Enrico P Veltri.Clinical Therapeutics . 2001 (8)